控制系统性硬化症指端溃疡与手功能改善相关
ECLIPSE 研究纳入 190 例既往一年内至少发生 1 次指端溃疡(DU)并接受波生坦治疗的系统性硬化症(SSc)患者,随访 1 年时 120 例有数据。38.3% 患者出现新发 DU,总体 DU 数、残疾评分、疼痛评分均改善,改善主要归于溃疡控制者。
要点
- 控制溃疡病活动 1 年与手部残疾显著减轻相关。
- 随访期间 38.3% 患者仍出现新发 DU 事件。
- 溃疡控制者 HAQ-DI、CHFS 和疼痛评分均显著改善。
核心结论
- 在 SSc 患者中,控制溃疡病活动 1 年与手部残疾显著减轻相关。
研究设计与样本
- ECLIPSE(研究 AC-052-517)为为期 2 年的前瞻性、多中心、观察性研究。
- 主要终点为入组时与 1 年后的残疾评分(CHFS、HAQ-DI)、疼痛评分(视觉模拟量表)和生活质量评分(SF-36)。
- 溃疡病控制定义为入组至 1 年随访期间无持续或新发 DU 事件。
主要发现
- 随访期间 46 例(38.3%)患者出现新发 DU 事件。
- 每例患者 DU 数从入组时 1.4 ± 1.8 降至 1 年时 0.6 ± 1.6(p < 0.0001)。
- HAQ-DI 从 1.0 ± 0.7 降至 0.9 ± 0.7(p = 0.04),CHFS 从 29 ± 20 降至 25 ± 20(p = 0.005)。
- 疼痛评分从 4.3 ± 3.1 降至 2.9 ± 2.8(p < 0.0001)。
- 改善归于溃疡病控制患者(48.3%),其 HAQ-DI(p = 0.04)、CHFS(p = 0.04)和疼痛评分(p = 0.046)显著改善。
关键数值与推荐
- 溃疡病控制定义为入组至 1 年随访期间无持续或新发 DU 事件。
- DU 数从 1.4 ± 1.8 降至 0.6 ± 1.6(p < 0.0001)。
- HAQ-DI 从 1.0 ± 0.7 降至 0.9 ± 0.7(p = 0.04)。
- CHFS 从 29 ± 20 降至 25 ± 20(p = 0.005)。
- 疼痛评分从 4.3 ± 3.1 降至 2.9 ± 2.8(p < 0.0001)。
临床怎么用
- 在 SSc 患者中,控制指端溃疡病活动可能有助于减轻手部残疾和疼痛。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Ischemic digital ulcers (DU) represent a major complication of systemic sclerosis (SSc). We investigated the impact of controlling the ulcerative disease on disability, pain, and quality of life in SSc patients receiving bosentan. METHODS: ECLIPSE (Study AC-052-517) is a 2-year prospective, multicenter, and observational study. Patients with SSc who experienced at least 1 DU in the previous year and received bosentan were included between October 2009 and March 2011. Disability scores [Cochin Hand Function Scale (CHFS) and Health Assessment Questionnaire Disability Index (HAQ-DI)], pain scores (visual analog scale), and quality-of-life scores (SF-36) were collected at inclusion and 1 year later (primary endpoint). A controlled ulcerative disease was defined by the absence of ongoing/new DU episode between inclusion and 1-year follow-up. RESULTS: Data were available at 1 year for 120 patients out of 190 included. During follow-up, 46 (38.3%) patients experienced a new DU episode. The number of DU per patient decreased from 1.4 ± 1.8 at inclusion to 0.6 ± 1.6 (p < 0.0001) at 1 year. Disability scores decreased from 1.0 ± 0.7 to 0.9 ± 0.7 (p = 0.04) for the HAQ-DI and from 29 ± 20 to 25 ± 20 (p = 0.005) for the CHFS; the pain score decreased from 4.3 ± 3.1 to 2.9 ± 2.8 (p < 0.0001). This improvement was attributed to patients with a controlled ulcerative disease (48.3%), who significantly improved HAQ-DI (p = 0.04), CHFS (p = 0.04), and pain score (p = 0.046). CONCLUSIONS: In patients with SSc, control of the ulcerative disease for 1 year was associated with significant attenuation of hand disability.
引用
- Mouthon L, Carpentier PH, Lok C, et al. Controlling the digital ulcerative disease in systemic sclerosis is associated with improved hand function. Semin Arthritis Rheum. 2017. PMID: 28214014. doi:10.1016/j.semarthrit.2017.01.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。